Navigation Links
UofL research holds promise of therapeutic approach for gum disease

University of Louisville researchers are a step closer to eliminating periodontal disease through their work to develop synthetic molecules that prevent a bacteria responsible for the disease from spreading throughout the mouth.

The discovery could lead to the formulation of a mouth rinse, toothpaste or tooth varnish to prevent the pathogen from establishing itself orally.

Donald Demuth, PhD, associate dean for research and enterprise, UofL School of Dentistry, received a patent today for his work to develop peptides that inhibit the interaction between P. gingivalis and Streptococcus gordonii and prevent P. gingivalis colonization of the mouth. Peptides are molecules formed when two or more amino acids join together; they are the building blocks of proteins in a cell.

"When P. gingivalis enters the oral environment, it seeks out interaction with the bacterium S. gordonii an otherwise benign organism in order to lay the ground work to propagate and ultimately gain a foothold below the gum line, leading to periodontal disease.

"UofL Oral Health and Systemic Disease Group director Richard Lamont characterized this bacterial interaction and based on those studies, my team developed a series of peptides that prevent P. gingivalis and S. gordonii from coming together," Demuth said.

Demuth found that administering the peptide in an animal model prevented P. gingivalis related bone loss the clinical symptom of periodontal disease -- and prevented the spread of the bacterium in the mouth.

"This is one of the first examples of a potential targeted therapeutic approach that may control periodontal disease," he said.

Demuth is building his research through collaboration with Frederick Luzzio, PhD, professor, UofL College of Arts & Sciences, Department of Chemistry. They hope to further develop organic molecule structures that mimic the active peptides.

"The molecules must be potent and cost effective to manufacture. We know of no chemical technology on the market that targets specific oral pathogens, and this is an exciting endeavor," Luzzio said.

Luzzio and Demuth have a patent pending on certain discoveries related to this research. The investigators are working with the Office of Technology Transfer at UofL to find an industrial partner to license and commercialize the technology.

Contact: Julie Heflin
University of Louisville

Related biology news :

1. WHOI researchers, collaborators receive $1.4 million grant to study life in oceans greatest depths
2. Researchers unravel genetic mechanism of fatty liver disease in obese children
3. UC research: Saving habitat key to songbirds survival
4. Montreal researchers repel mortality in Malian mothers
5. UF researchers look for ways to make an emerging technology safe for environment
6. Brandeis scientists win prestigious prize for circadian rhythms research
7. UCSB researchers to examine the effects of year-old NOAA West Coast Catch Shares program
8. New paper by Notre Dame researchers describes method for cleaning up nuclear waste
9. SDSCs big data expertise aiding genomics research
10. Young researcher taking fight against global killer to the next level in Vietnam
11. Space research institute honors Sen. Hutchison with Pioneer Award
Post Your Comments:
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
Breaking Biology Technology: